In a major development in the fluid management solutions (filtration, separations and purification) space in the country for the pharma and biotech sector, Pall India Pvt. Ltd, the 100 per cent subsidiary of Pall Corporation global leader, has commissioned a Centre of Excellence in Bangalore.
The facility, which spans 20,000 sq. ft. spreads over three floors, is equipped with the latest equipment. It is the largest proteomics laboratory to help customers speed drug discovery process. It houses a validation lab and a training facility with specialty experts to support the Indian and regional customers as they enter the regulated drug export market, stated Vinay Gupta, managing director, Pall India Private Limited at the press conclave post inauguration of the facility at JP Nagar in Bangalore.
The 24/7 centre will offer expertise to all global locations from Bangalore. It will have total manpower strength of 60 where 30 have already been hired who mainly constitute scientists.
India has been choice for the new Centre of Excellence in Asia because of its efforts in life sciences which cover the biopharmaceutical research, development and production. The country also has a vast pool of scientific personnel to provide the ideal environ for innovation and growth. India is a vital market going by the capabilities of the company and the centre of excellence is expected to provide a boost to the bio-pharma development in the country, stated Ken Frank, vice president corporate, Biopharmaceuticals, Pall Corporation.
The new centre for excellence joins other Pall's Life Sciences Centres in US and Europe. It will offer the latest technologies with process optimisation knowledge and expertise. Customers in the pharma biotech research, drug development and process applications will be able to carry out all stages of activities efficiently and a cost-effective manner, stated Vinay Jobanputra, senior vice president, and general manager, Pall India.
Indian pharma industry is ranked globally as fourth in terms of volume. India holds $6 billion of the $550 billion global pharma industry, an annual increase of 10 per cent compared to the 7 per cent of the annual growth of the global market. The biotech sector will touch 10 billion by 2010.
Prof Rao president, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore who was the chief guest stated that proteomics an genomics were to two crucial arms of the modern biology. Proteomics has taken to the level of sophistication for diagnostics and prognostics market. driving the drug therapy development and diagnostics. "India is emerging as a hub for centres of excellence of the multinational companies. With the available human resources and infrastructure, the country is converging for a discovery of potential targets and molecules. The country is already capitalizing on the knowledge and infrastructure going by the scores of government initiated programmes. Dr Rao himself is leading a CSIR sponsored cancer genomics research project with an industry partner Dabur.
The global value of the fluid managements solutions market, Proteomics research and separation technologies is valued between $ 800 million to $ one billion. Process and manufacture sector constitute $ two billion and therapy market is $ two billion, stated Ken Harris, Pall Corporation.